Produktname:(4-(1-methyl-1H-pyrazol-4-yl)phenyl)methanamine

IUPAC Name:1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methanamine

CAS:1184589-25-0
Molekulare Formel:C11H13N3
Reinheit:95%+
Katalognummer:CM362822
Molekulargewicht:187.25

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM362822-1g in stock --

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:1184589-25-0
Molekulare Formel:C11H13N3
Schmelzpunkt:-
SMILES-Code:CN1C=C(C=N1)C1=CC=C(CN)C=C1
Dichte:
Katalognummer:CM362822
Molekulargewicht:187.25
Siedepunkt:
Mdl-Nr.:
Lagerung:

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.

Column Infos

IDRX-42
IDRx announces $120 million series B financing to advance potential best-in-class new treatment for gastrointestinal stromal tumor (GIST). IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant GIST (including variants in exons 9, 11, 13 and 17). IDRX-42 was granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 is currently being evaluated in StrateGIST 1, a first-in-human Phase 1/1b study.
In preclinical studies, IDRX-42 demonstrated superior antitumor activity compared to imatinib, the current first-line of therapy, in GIST human xenograft models expressing mutations in KIT exons 9 and 11. In xenograft models expressing secondary resistance mutations in KIT exon 13 or 17, IDRX-42 treatment resulted in potent and dose-dependent antitumor activity superior to the second-line standard of care agent, sunitinib.